Regulus Therapeutics, a biopharmaceutical company founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals (ISIS), announced today that it has filed a registration statement on Form S-1 with the SEC relating to a proposed IPO. All shares of the common stock to be sold in the offering will be offered by Regulus.